3SBio Inc. (1530.HK)
1530.HK Stock Price Chart
Explore 3SBio Inc. interactive price chart. Choose custom timeframes to analyze 1530.HK price movements and trends.
1530.HK Company Profile
Discover essential business fundamentals and corporate details for 3SBio Inc. (1530.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Jun 2015
Employees
5.58K
Website
https://www.3sbio.comCEO
Jing Lou
Description
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
1530.HK Financial Timeline
Browse a chronological timeline of 3SBio Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Mar 2026
Earnings released on 20 Aug 2025
Dividend declared on 21 Jul 2025
A dividend of $0.25 per share was announced, adjusted to $0.25. The dividend was paid on 15 Aug 2025.
Earnings released on 25 Mar 2025
EPS came in at $0.43 falling short of the estimated $0.46 by -7.01%, while revenue for the quarter reached $5.02B , beating expectations by +3.23%.
Earnings released on 22 Aug 2024
EPS came in at $0.48 surpassing the estimated $0.47 by +1.78%, while revenue for the quarter reached $4.71B , beating expectations by +0.81%.
Dividend declared on 22 Jul 2024
A dividend of $0.25 per share was announced, adjusted to $0.25. The dividend was paid on 5 Aug 2024.
Earnings released on 21 Mar 2024
EPS came in at $0.26 falling short of the estimated $0.44 by -41.38%, while revenue for the quarter reached $4.46B , missing expectations by -2.21%.
Earnings released on 24 Aug 2023
EPS came in at $0.43 surpassing the estimated $0.38 by +14.75%, while revenue for the quarter reached $4.09B , beating expectations by +6.00%.
Dividend declared on 27 Jun 2023
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 11 Jul 2023.
Earnings released on 22 Mar 2023
EPS came in at $0.41 surpassing the estimated $0.41 by +1.10%, while revenue for the quarter reached $4.30B , missing expectations by -1.89%.
Earnings released on 24 Aug 2022
EPS came in at $0.42 surpassing the estimated $0.35 by +20.49%, while revenue for the quarter reached $3.62B , missing expectations by -10.97%.
Dividend declared on 27 Jun 2022
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 11 Jul 2022.
Earnings released on 29 Mar 2022
EPS came in at $0.33 surpassing the estimated $0.31 by +8.25%, while revenue for the quarter reached $4.01B , missing expectations by -7.32%.
Earnings released on 25 Aug 2021
EPS came in at $0.39 surpassing the estimated $0.38 by +1.43%, while revenue for the quarter reached $3.73B , missing expectations by -1.88%.
Earnings released on 31 Mar 2021
EPS came in at $0.06 falling short of the estimated $0.31 by -81.46%, while revenue for the quarter reached $3.44B , missing expectations by -13.63%.
1530.HK Stock Performance
Access detailed 1530.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.